NCT03206931No Longer Available不适用
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Bayer
研究概览
简要总结
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 1 Month 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
- •Previous treatment with a kinase inhibitor with known activity on TRK inhibition
- •Unable to participate in an ongoing selitrectinib clinical trial
- •Medically suitable for treatment with selitrectinib
排除标准
- •Currently enrolled in an ongoing clinical study with a TRK inhibitor
研究者
相似试验
No Longer Available
不适用
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) MutationsNCT03409081Astellas Pharma Global Development, Inc.
Unknown
不适用
Expanded Access Use of Cemiplimab in Patients With Solid TumorsNCT06132191Regeneron Pharmaceuticals
No Longer Available
不适用
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene FusionsCancers With NTRK, ROS1, or ALK Gene FusionsNCT03066661Hoffmann-La Roche
Approved For Marketing
不适用
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationNon Small Cell Lung CancerMedullary Thyroid CancerPapillary Thyroid CancerOther Solid Tumors With Evidence of Activating RET AlterationBreast CancerPancreatic CancerColon CancerNCT03906331Eli Lilly and Company
Available
不适用
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesSmall Bowel CancerNon Small Cell Lung CancerHead and Neck CancerMAPK Gene MutationKRAS Activating MutationBRAF Gene MutationNRAS Gene MutationHRAS Gene MutationMEK MutationERK MutationColorectal CancerOvarian CancerHepatocellular CarcinomaPancreatic CancerGastric CancerMelanomaBladder CancerGlioblastomaEsophageal CancerThyroid CancerCholangiocarcinomaNCT04566393xCures